Zymeworks Announces China Nmpa Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.